193 related articles for article (PubMed ID: 27549189)
1. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Díaz-Núñez M; Díez-Torre A; De Wever O; Andrade R; Arluzea J; Silió M; Aréchaga J
BMC Cancer; 2016 Aug; 16(1):667. PubMed ID: 27549189
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of annexin A1 expression by butyrate in human melanoma cells induces invasion by inhibiting E-cadherin expression.
Shin J; Song IS; Pak JH; Jang SW
Tumour Biol; 2016 Nov; 37(11):14577-14584. PubMed ID: 27612479
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
6. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias.
D'Amato L; Dell'Aversana C; Conte M; Ciotta A; Scisciola L; Carissimo A; Nebbioso A; Altucci L
Epigenetics; 2015; 10(1):6-18. PubMed ID: 25494542
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
[TBL] [Abstract][Full Text] [Related]
8. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.
Kim NH; Kim SN; Kim YK
Biochem Biophys Res Commun; 2011 Jan; 404(4):915-21. PubMed ID: 21184735
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel.
Kuwajima A; Iwashita J; Murata J; Abe T
Anticancer Res; 2007; 27(6B):4163-9. PubMed ID: 18225587
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
11. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Mahal K; Kahlen P; Biersack B; Schobert R
Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
[TBL] [Abstract][Full Text] [Related]
12. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
Jordaan G; Liao W; Sharma S
BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Law ME; Corsino PE; Jahn SC; Davis BJ; Chen S; Patel B; Pham K; Lu J; Sheppard B; Nørgaard P; Hong J; Higgins P; Kim JS; Luesch H; Law BK
Oncogene; 2013 Mar; 32(10):1316-29. PubMed ID: 22543582
[TBL] [Abstract][Full Text] [Related]
15. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
De los Santos M; Martínez-Iglesias O; Aranda A
Endocr Relat Cancer; 2007 Dec; 14(4):1021-8. PubMed ID: 18045953
[TBL] [Abstract][Full Text] [Related]
16. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Mühlethaler-Mottet A; Meier R; Flahaut M; Bourloud KB; Nardou K; Joseph JM; Gross N
Mol Cancer; 2008 Jun; 7():55. PubMed ID: 18549473
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
18. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
[TBL] [Abstract][Full Text] [Related]
20. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
